All publications and patent applications mentioned in this specification are herein incorporated by reference in their entirety to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.
Described herein are tip components, devices, systems and methods for effectively steering a catheter through turns in the vasculature.
Catheters are commonly used in medicine for delivery of fluids, therapeutics and implants as well as in sampling tissues and bodily fluids. Catheters can be constructed with balloons or other tools to dilate tissue, block fluid flow or isolate segments of the anatomy. A relatively common use for a catheter is the delivery of drugs to a target tissue using blood vessels as a means of access. When a balloon is used, the vascular compartment distal to the balloon is isolated from the vascular compartment proximal to the balloon and perfusion of diagnostic, therapeutic or embolic agents is localized and concentrated. Transvascular catheters, especially in the peripheral blood circulation, need to have a small diameter to allow access into small vessels.
One common use for a microcatheter is the delivery of embolic agents and anticancer drugs to a tumor.
According to the NIH, 30,640 people were diagnosed with primary liver cancer (hepatocellular carcinoma, HCC) and 142,820 people were diagnosed with colorectal cancer in the US in 2013. Seventy five percent of these will metastasize to the liver. Liver resection and transplant are the only curative means; however, only small numbers of patients are eligible. Systemic Chemotherapy for primary and metastatic tumors in the liver is ineffective, having a response rate of about 20% and a survival benefit of 10.7 months vs. 7.9 months over symptomatic care.
Trans-Arterial Embolization therapy is the transvascular access for injection of drug and/or embolic agents directly into, or in the vicinity of, the tumor vasculature using a microcatheter. Embolization therapy causes a shutdown of blood flow and, when drug or radioactivity is present, simultaneous release of high concentrations of drug or radioactivity. The technique is also noted for its very low level of toxicity. Chemoembolization was established as a standard of care for intermediate stage hepatocellular carcinoma in 2006. Numerous studies have demonstrated transarterial embolization to be effective on a number of primary cancers and to have better performance than chemotherapy for both HCC and metastatic colorectal cancers in the liver.
Various prior art references provide guidance on aspects of medical catheter construction. For example, U.S. patent application Ser. No. 10/128,977 describes a coaxial catheter whereby a balloon is bonded to an elongated outer tube to prevent the balloon from telescopingly buckling when the balloon is being pushed across a narrow passage. U.S. Pat. No. 6,066,157 describes a coaxial coronary angioplasty catheter whereby an anchor joint is configured to allow distal movement of the inner tube and to prevent proximal movement. U.S. Pat. No. 5,647,198 describes a catheter with a pair of spaced apart balloons that define an intra-balloon space. A lumen passes through the catheter and exits within the intra-balloon space allowing injection of drugs, emulsions, fluids and fluid/solid mixtures. A perfusion lumen or bypass extends from a location proximal to the proximal balloon and to the distal tip to allow shunting of blood past the inflated balloons. U.S. Pat. No. 5,674,198 describes a two balloon catheter that is designed for treating a solid tumor. The balloons are positioned to isolate the blood flow into the tumor and allow injection of a vaso-occlusive collagen material to block the tumor blood supply. Clifton et al. (1963) Cancer 16:444-452 describes a two balloon catheter for the treatment of lung carcinoma. The four lumen catheter includes a lumen for independent injection in the space between the balloons. Rousselot et al. (1965) JAMA 191:707-710 describes a balloon catheter device for delivering anticancer drugs into the liver. See also U.S. Pat. Nos. 6,780,181; 6,835,189; 7,144,407; 7,412,285; 7,481,800; 7,645,259; 7,742,811; U.S. App. No. 2001/008451; U.S. App. No. 2001/0041862; U.S. App. No. 2003/008726; U.S. App. No. 2003/0114878; U.S. App. No. 2005/0267407; U.S. App. No. 2007/0137651; U.S. App. No. 2008/0208118; U.S. App. No. 2009/0182227 and U.S. App. No. 2010/0114021.
Medical catheters often are advanced through torturous vasculature, requiring a flexible distal section that can easily follow the vessel and a stiff proximal section that can support longitudinal advancement of the catheter as it twists and turns through the blood vessels. It is also desirable, in certain applications, that the catheter can transmit torque throughout its length, from the proximal end to the distal tip. This is particularly true when a shaped catheter tip is used. Shaped catheter tips are common and used to direct a guidewire and/or a catheter around acute angles and into branch vessels. A 90-degree shape is among the favored tip configurations. In use, the catheter tip is rotationally oriented so that the angled tip is pointed toward the desired direction of travel and then the guidewire is further advanced into the vasculature. However, tracking a catheter through tortuous vasculature remains a challenging and time consuming process.
Accordingly, there remains an unmet medical need for an improved catheter having a shaped tip that facilitates navigation through tortuous vasculature.
In some embodiments of the present disclosure, a vascular catheter system is provided with a flexible main body and a flexible shaped tip. The flexible main body extends along a generally straight longitudinal axis when in a relaxed state and has a proximal end and a distal end. The main body also has a lumen therethrough configured to slidably receive a guidewire. The flexible shaped tip is located at the distal end of the main body. The shaped tip has a lumen therethrough that is in communication with the lumen of the main body and is configured to slidably receive a guidewire. The shaped tip has at least a portion configured to deviate from the longitudinal axis when in a relaxed state and configured to move towards alignment with the longitudinal axis when a guidewire is extended through the lumen of the shaped tip. The shaped tip is no longer than 1 cm and comprises at least three sections including a first, a second and a third section. The second section is located distally from the first section and the third section is located distally from the second section. The second section includes a first material having a first durometer and a second material having a second durometer lower than the first durometer. The second material includes a polymer and tungsten. The first section includes the first material without the second material, and the third section includes the second material without the first material.
In some of the above embodiments, the portion of the shaped tip configured to deviate from the longitudinal axis extends through an angle of at least 30 degrees. The portion of the shaped tip configured to deviate from the longitudinal axis may extend through an angle of between about 60 and about 90 degrees. In some embodiments, the portion of the shaped tip configured to deviate from the longitudinal axis extends through an angle of between about 120 and about 160 degrees.
Some embodiments of the system further include a guidewire configured to be received through the main body and the shaped tip to guide a distal end of the shaped tip through torturous vasculature. A distal region of the guidewire may increase in stiffness when moving from its distal end towards its proximal end. The system may further include an inflatable balloon located near the distal end of the main body.
In some embodiments, the shaped tip includes a single bend. In other embodiments, the shaped tip includes at least two bends. The shaped tip may include a curved portion having an inner bend radius no greater than about 0.10 inches. The shaped tip may include a curved portion having an inner bend radius no greater than about three times an outside diameter of the shaped tip.
In some embodiments of the present disclosure, a method of manufacturing a vascular catheter system is provided. The method may include the steps of providing a flexible main body, and forming and bonding a flexible shaped tip to the distal end of the main body. The flexible main body may extend along a generally straight longitudinal axis when in a relaxed state. The main body has a proximal end and a distal end and may have a lumen therethrough configured to slidably receive a guidewire. The shaped tip may be provided with a lumen therethrough in communication with the lumen of the main body and configured to slidably receive a guidewire. In some embodiments, the shaped tip has at least a portion configured to deviate from the longitudinal axis when in a relaxed state and configured to move towards alignment with the longitudinal axis when a guidewire is extended through the lumen of the shaped tip. In some embodiments, the shaped tip is no longer than 1 cm and comprises at least three sections including a first, a second and a third section. The second section is located distally from the first section and the third section is located distally from the second section. The second section may include a first material having a first durometer and a second material having a second durometer lower than the first durometer. The second material may include a polymer and tungsten. In some embodiments, first section includes the first material without the second material, and the third section includes the second material without the first material.
In some of the above embodiments, the first durometer is 35D and the second durometer is 25D. The forming and bonding step may include placing a first tube made of the first material partially over the distal end of the main body and heating the first tube such that it reflows onto the main body and bonds therewith. The forming and bonding step may further include placing a second tube made of the second material partially over a distal end of the first tube and heating the first tube and second tube such that they reflow and bond together. In some embodiments, the first tube and the second tube are each no longer than about 4 mm. In some embodiments, the first tube overlaps with the main body no more than about 2 mm and the second tube overlaps with the first tube no more than about 2 mm.
In some embodiments, the forming and bonding step further includes placing a tube made of heat shrink material over at least one of the first tube and the second tube, heating the heat shrink material until it shrinks and causes a diameter of at least one of the first tube and the second tube to shrink, and then removing the heat shrink material. The forming and bonding step may further include forming a taper on a distal end of the second tube by placing a tube made of heat shrink material over the distal end of the second tube, heating the heat shrink material until it shrinks and causes a diameter of distal end of the second tube to shrink more than a diameter of a proximal portion of the second tube, and then removing the heat shrink material.
The methods may further include a step of changing the shape of the first and second tubes after they have been reflowed together. This step may include using a mandrel or mold to hold the first and second tubes in a non-straight position while heating the first and second tubes to a temperature that is lower than a temperature that was used to reflow the first and second tubes together. This non-straight position may include a curve extending more than 90 degrees.
The novel features of the disclosure are set forth with particularity in the claims that follow. A better understanding of the features and advantages of the present disclosure will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the disclosure are utilized, and the accompanying drawings of which:
Described herein are catheter designs that allow a shaped tip to be more easily navigated through tortuous vasculature. Termination of the catheter at a flexible, soft tip is desirable to minimize vessel trauma. The added support of a rigid section in proximity to the distal tip further aides in catheter tracking as a flexible section (without support or reinforcement) would be prone to kink and excessive flexing.
As shown in
The first annular volume described above is in fluid communication inside Y-hub 110 with its lateral port 128. The second annular volume is in fluid communication with the interior of balloon 120. Accordingly, when a balloon inflation pressure is provided at lateral port 128, balloon 120 inflates as shown in
In some embodiments, catheter system 100 may have a working length A (i.e. outside of Y-hub 110 and strain relief 114) of about 50 cm to about 180 cm. In some embodiments, the length B of distal outer catheter section 118 is about 30 cm. In some embodiments, the diameter of balloon 120 is about 7 mm, its length is about 8 mm, and the length of distal tip segment 124 is about 8 mm. This results in a combined distance C of balloon and tip of about 1.5 cm, and a total distance B+C distal to junction point 126 of about 31.5 cm. For embodiments having a working length A of 150 cm, this leaves a length D of about 119.5 cm for the portion of proximal outer catheter section 116 that extends from Y-hub 110 and strain relief 114. In some implementations, catheter system 100 is introduced into the target vasculature through a diagnostic catheter (not shown.) In some of these implementations, it is desirable to have about 20 cm of flexible catheter section (e.g. B+C) extending from the diagnostic catheter in order to track through tortuous vasculature. Therefore, with the aforementioned dimensions, junction point 126 and the distal portion of proximal outer catheter section 116 remain inside the diagnostic catheter during a medical procedure.
Referring to
Referring to
As shown in
As depicted in
Referring to
In the construct depicted in
Tube A may be oversized so that its proximal end slides over the distal end of inner catheter 112. Heating tube A (before or after tubes B and W are added) allows tube A to shrink to fit over inner catheter 112. The three tubes A, B and W may then be heated to melt and bond together and to inner catheter 112 using a material reflow process. The multiple layers may be processed in parallel or in series. In the middle section of
Referring to
Referring to
Referring to
Referring to
In the exemplary embodiments depicted in
Referring to
After a straight catheter tip is formed, such as previously described, it may be shaped into a non-straight configuration. For example, tip 150 shown in
Referring to
Referring to
Prior art shaped tips are typically made of a single material and often have lengths between about 1.5 and 3.0 cm in length. Using the fabrication techniques disclosed herein, similar bend profiles can be achieved in a shorter distance. In some embodiments, the lengths of the inventive tips extending beyond the base catheter are between 0.3 and 1.0 cm. These shorter lengths allow for the catheter to be maneuvered through tighter turns in the vasculature while minimizing the distance from the distal tip of the catheter to an operational interface such as a balloon. This allows accurate positioning of the operational interface and distal tip for the desired application, such as therapeutic delivery.
In one particular exemplary embodiment, a shaped tip is formed from two Pebax® tubes in a starting configuration similar to that shown in
In this exemplary embodiment, the following steps may be performed to form and bond the distal tip on the end of an inner catheter:
After the above reflow process, the following steps may be performed to create a taper on the distal tip:
After the above taper process, the following steps may be performed to shape the distal tip:
In another embodiment similar to the construct shown in
The shaped catheter tips disclosed herein created by layering or abutting different materials can offer improved bend profiles, transition from rigid to flexible in a gradient rather than abrupt changes which in turn can reduce kinking of the catheter tip, and can provide sharper bends in a shorter length of catheter tip in order to more easily navigate through tight bends in the vasculature.
When a feature or element is herein referred to as being “on” another feature or element, it can be directly on the other feature or element or intervening features and/or elements may also be present. In contrast, when a feature or element is referred to as being “directly on” another feature or element, there are no intervening features or elements present. It will also be understood that, when a feature or element is referred to as being “connected”, “attached” or “coupled” to another feature or element, it can be directly connected, attached or coupled to the other feature or element or intervening features or elements may be present. In contrast, when a feature or element is referred to as being “directly connected”, “directly attached” or “directly coupled” to another feature or element, there are no intervening features or elements present. Although described or shown with respect to one embodiment, the features and elements so described or shown can apply to other embodiments. It will also be appreciated by those of skill in the art that references to a structure or feature that is disposed “adjacent” another feature may have portions that overlap or underlie the adjacent feature.
Terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the disclosure. For example, as used herein, the singular forms “a”, “an” and “the” are intended to include the plural forms as well, unless the context clearly indicates otherwise. It will be further understood that the terms “comprises” and/or “comprising,” when used in this specification, specify the presence of stated features, steps, operations, elements, and/or components, but do not preclude the presence or addition of one or more other features, steps, operations, elements, components, and/or groups thereof. As used herein, the term “and/or” includes any and all combinations of one or more of the associated listed items and may be abbreviated as “/”.
Spatially relative terms, such as “under”, “below”, “lower”, “over”, “upper” and the like, may be used herein for ease of description to describe one element or feature's relationship to another element(s) or feature(s) as illustrated in the figures. It will be understood that the spatially relative terms are intended to encompass different orientations of the device in use or operation in addition to the orientation depicted in the figures. For example, if a device in the FIGS. is inverted, elements described as “under” or “beneath” other elements or features would then be oriented “over” the other elements or features. Thus, the exemplary term “under” can encompass both an orientation of over and under. The device may be otherwise oriented (rotated 90 degrees or at other orientations) and the spatially relative descriptors used herein interpreted accordingly. Similarly, the terms “upwardly”, “downwardly”, “vertical”, “horizontal” and the like are used herein for the purpose of explanation only unless specifically indicated otherwise.
Although the terms “first” and “second” may be used herein to describe various features/elements (including steps), these features/elements should not be limited by these terms, unless the context indicates otherwise. These terms may be used to distinguish one feature/element from another feature/element. Thus, a first feature/element discussed below could be termed a second feature/element, and similarly, a second feature/element discussed below could be termed a first feature/element without departing from the teachings of the present disclosure.
Throughout this specification and the claims which follow, unless the context requires otherwise, the word “comprise”, and variations such as “comprises” and “comprising” means various components can be co-jointly employed in the methods and articles (e.g., compositions and apparatuses including device and methods). For example, the term “comprising” will be understood to imply the inclusion of any stated elements or steps but not the exclusion of any other elements or steps.
In general, any of the apparatuses and methods described herein should be understood to be inclusive, but all or a sub-set of the components and/or steps may alternatively be exclusive, and may be expressed as “consisting of” or alternatively “consisting essentially of” the various components, steps, sub-components or sub-steps.
As used herein in the specification and claims, including as used in the examples and unless otherwise expressly specified, all numbers may be read as if prefaced by the word “about” or “approximately,” even if the term does not expressly appear. The phrase “about” or “approximately” may be used when describing magnitude and/or position to indicate that the value and/or position described is within a reasonable expected range of values and/or positions. For example, a numeric value may have a value that is +/−0.1% of the stated value (or range of values), +/−1% of the stated value (or range of values), +/−2% of the stated value (or range of values), +/−5% of the stated value (or range of values), +/−10% of the stated value (or range of values), etc. Any numerical values given herein should also be understood to include about or approximately that value, unless the context indicates otherwise. For example, if the value “10” is disclosed, then “about 10” is also disclosed. Any numerical range recited herein is intended to include all sub-ranges subsumed therein. It is also understood that when a value is disclosed that “less than or equal to” the value, “greater than or equal to the value” and possible ranges between values are also disclosed, as appropriately understood by the skilled artisan. For example, if the value “X” is disclosed the “less than or equal to X” as well as “greater than or equal to X” (e.g., where X is a numerical value) is also disclosed. It is also understood that the throughout the application, data is provided in a number of different formats, and that this data, represents endpoints and starting points, and ranges for any combination of the data points. For example, if a particular data point “10” and a particular data point “15” are disclosed, it is understood that greater than, greater than or equal to, less than, less than or equal to, and equal to 10 and 15 are considered disclosed as well as between 10 and 15. It is also understood that each unit between two particular units are also disclosed. For example, if 10 and 15 are disclosed, then 11, 12, 13, and 14 are also disclosed.
Although various illustrative embodiments are described above, any of a number of changes may be made to various embodiments without departing from the scope of the disclosure as described by the claims. For example, the order in which various described method steps are performed may often be changed in alternative embodiments, and in other alternative embodiments one or more method steps may be skipped altogether. Optional features of various device and system embodiments may be included in some embodiments and not in others. Therefore, the foregoing description is provided primarily for exemplary purposes and should not be interpreted to limit the scope of the disclosure as it is set forth in the claims.
The examples and illustrations included herein show, by way of illustration and not of limitation, specific embodiments in which the subject matter may be practiced. As mentioned, other embodiments may be utilized and derived there from, such that structural and logical substitutions and changes may be made without departing from the scope of this disclosure. Such embodiments of the inventive subject matter may be referred to herein individually or collectively by the term “invention” or “disclosure” merely for convenience and without intending to voluntarily limit the scope of this application to any single invention or inventive concept, if more than one is, in fact, disclosed. Thus, although specific embodiments have been illustrated and described herein, any arrangement calculated to achieve the same purpose may be substituted for the specific embodiments shown. This disclosure is intended to cover any and all adaptations or variations of various embodiments. Combinations of the above embodiments, and other embodiments not specifically described herein, will be apparent to those of skill in the art upon reviewing the above description.
Number | Name | Date | Kind |
---|---|---|---|
4198981 | Sinnreich | Apr 1980 | A |
4545390 | Leary | Oct 1985 | A |
4581017 | Sahota | Apr 1986 | A |
4737153 | Shimamura et al. | Apr 1988 | A |
4748982 | Horzewski et al. | Jun 1988 | A |
4892519 | Songer et al. | Jan 1990 | A |
4896669 | Bhate et al. | Jan 1990 | A |
4898591 | Jang | Feb 1990 | A |
4909252 | Goldberger | Mar 1990 | A |
4944745 | Sogard et al. | Jul 1990 | A |
4976690 | Solar et al. | Dec 1990 | A |
4990143 | Sheridan | Feb 1991 | A |
5000734 | Boussignac et al. | Mar 1991 | A |
5040548 | Yock | Aug 1991 | A |
5045072 | Castillo | Sep 1991 | A |
5047045 | Arney et al. | Sep 1991 | A |
5078685 | Colliver | Jan 1992 | A |
5090958 | Sahota | Feb 1992 | A |
5100386 | Inoue | Mar 1992 | A |
5137513 | Mcinnes et al. | Aug 1992 | A |
5156594 | Keith et al. | Oct 1992 | A |
5217434 | Arney | Jun 1993 | A |
5234416 | Macaulay | Aug 1993 | A |
5254107 | Soltesz | Oct 1993 | A |
5279562 | Sirhan et al. | Jan 1994 | A |
5334154 | Samson et al. | Aug 1994 | A |
5342386 | Trotta | Aug 1994 | A |
5356388 | Sepetka et al. | Oct 1994 | A |
5370655 | Burns | Dec 1994 | A |
5423754 | Cornelius et al. | Jun 1995 | A |
5423829 | Pham et al. | Jun 1995 | A |
5429605 | Richling: Bernd | Jul 1995 | A |
5454795 | Samson | Oct 1995 | A |
5470314 | Walinsky | Nov 1995 | A |
5484409 | Atkinson et al. | Jan 1996 | A |
5498251 | Dalton | Mar 1996 | A |
5501667 | Verduin | Mar 1996 | A |
5509910 | Lunn | Apr 1996 | A |
5538510 | Fontirroche et al. | Jul 1996 | A |
5556383 | Wang et al. | Sep 1996 | A |
5582619 | Ken | Dec 1996 | A |
5584821 | Hobbs et al. | Dec 1996 | A |
5588442 | Scovil et al. | Dec 1996 | A |
5599326 | Carter | Feb 1997 | A |
5624449 | Pham et al. | Apr 1997 | A |
5637086 | Ferguson et al. | Jun 1997 | A |
5643254 | Scheldrup et al. | Jul 1997 | A |
5647198 | Mihailovic | Jul 1997 | A |
5649949 | Wallace et al. | Jul 1997 | A |
5658263 | Dang | Aug 1997 | A |
5669905 | Scheldrup et al. | Sep 1997 | A |
5674198 | Leone | Oct 1997 | A |
5690666 | Berenstein et al. | Nov 1997 | A |
5690667 | Gia | Nov 1997 | A |
5718711 | Berenstein et al. | Feb 1998 | A |
5722424 | Engelson | Mar 1998 | A |
5749837 | Palermo et al. | May 1998 | A |
5766192 | Zacca | Jun 1998 | A |
5769830 | Parker | Jun 1998 | A |
5775327 | Randolph | Jul 1998 | A |
5792300 | Inderbitzen et al. | Aug 1998 | A |
5797874 | Spears | Aug 1998 | A |
5800454 | Jacobsen et al. | Sep 1998 | A |
5807355 | Ramzipoor et al. | Sep 1998 | A |
5820592 | Hammerslag | Oct 1998 | A |
5830182 | Wang et al. | Nov 1998 | A |
5833705 | Ken et al. | Nov 1998 | A |
5843032 | Kastenhofer | Dec 1998 | A |
5843050 | Jones et al. | Dec 1998 | A |
5851203 | Van Muiden | Dec 1998 | A |
5853418 | Ken et al. | Dec 1998 | A |
5868704 | Campbell et al. | Feb 1999 | A |
5879324 | von Hoffmann | Mar 1999 | A |
5891128 | Gia et al. | Apr 1999 | A |
5911717 | Jacobsen et al. | Jun 1999 | A |
5938653 | Pepin | Aug 1999 | A |
5951539 | Nita et al. | Sep 1999 | A |
5951929 | Wilson | Sep 1999 | A |
5984878 | Engelson | Nov 1999 | A |
5984929 | Bashiri et al. | Nov 1999 | A |
6013084 | Ken et al. | Jan 2000 | A |
6014919 | Jacobsen et al. | Jan 2000 | A |
6019757 | Scheldrup | Feb 2000 | A |
6022340 | Sepetka et al. | Feb 2000 | A |
6036382 | Lange et al. | Mar 2000 | A |
6036670 | Wijeratne et al. | Mar 2000 | A |
6066157 | Barbere | May 2000 | A |
6066667 | Ashbrook | May 2000 | A |
6071286 | Mawad | Jun 2000 | A |
6090099 | Samson et al. | Jul 2000 | A |
6103037 | Wilson | Aug 2000 | A |
6123714 | Gia et al. | Sep 2000 | A |
6156061 | Wallace et al. | Dec 2000 | A |
6165163 | Chien et al. | Dec 2000 | A |
6187027 | Mariant et al. | Feb 2001 | B1 |
6190358 | Fitzmaurice et al. | Feb 2001 | B1 |
6190393 | Bevier et al. | Feb 2001 | B1 |
6203547 | Nguyen et al. | Mar 2001 | B1 |
6258080 | Samson | Jul 2001 | B1 |
6270495 | Palermo | Aug 2001 | B1 |
6280457 | Wallace et al. | Aug 2001 | B1 |
6287301 | Thompson et al. | Sep 2001 | B1 |
6319228 | Kastenhofer | Nov 2001 | B1 |
6344041 | Kupiecki et al. | Feb 2002 | B1 |
6397850 | Scheldrup et al. | Jun 2002 | B1 |
6423085 | Murayama et al. | Jul 2002 | B1 |
6428489 | Jacobsen et al. | Aug 2002 | B1 |
6440088 | Jacobsen et al. | Aug 2002 | B1 |
6468266 | Bashiri et al. | Oct 2002 | B1 |
6471673 | Kastenhofer | Oct 2002 | B1 |
6508804 | Sarge et al. | Jan 2003 | B2 |
6553880 | Jacobsen et al. | Apr 2003 | B2 |
6575959 | Sarge et al. | Jun 2003 | B1 |
6579246 | Jacobsen et al. | Jun 2003 | B2 |
6635069 | Teoh et al. | Oct 2003 | B1 |
6638245 | Miller et al. | Oct 2003 | B2 |
6648874 | Parisi | Nov 2003 | B2 |
6652508 | Griffin et al. | Nov 2003 | B2 |
6656550 | Zamore | Dec 2003 | B1 |
6702782 | Miller et al. | Mar 2004 | B2 |
6702802 | Hancock et al. | Mar 2004 | B1 |
6706025 | Engelson et al. | Mar 2004 | B2 |
6766720 | Jacobsen et al. | Jul 2004 | B1 |
6780181 | Kroll et al. | Aug 2004 | B2 |
6835189 | Musbach et al. | Dec 2004 | B2 |
6849062 | Kantor | Feb 2005 | B2 |
6860893 | Wallace et al. | Mar 2005 | B2 |
6860899 | Rivelli | Mar 2005 | B1 |
6878151 | Carrison et al. | Apr 2005 | B2 |
6921410 | Porter | Jul 2005 | B2 |
6936055 | Ken et al. | Aug 2005 | B1 |
6997937 | Jacobsen et al. | Feb 2006 | B2 |
7004962 | Stinson | Feb 2006 | B2 |
7037330 | Rivelli et al. | May 2006 | B1 |
7060083 | Gerberding | Jun 2006 | B2 |
7070607 | Murayama et al. | Jul 2006 | B2 |
7144407 | Lasersohn | Dec 2006 | B1 |
7153323 | Teoh et al. | Dec 2006 | B1 |
7166122 | Aganon et al. | Jan 2007 | B2 |
7294137 | Rivelli et al. | Nov 2007 | B2 |
7332689 | Mertens et al. | Feb 2008 | B2 |
7412285 | Schroeppel et al. | Aug 2008 | B2 |
7468070 | Henry et al. | Dec 2008 | B2 |
7481800 | Jacques | Jan 2009 | B2 |
7621904 | McFerran et al. | Nov 2009 | B2 |
7645259 | Goldman | Jan 2010 | B2 |
7654979 | Simpson | Feb 2010 | B2 |
7742811 | Schroeppel et al. | Jun 2010 | B2 |
7780626 | Wu et al. | Aug 2010 | B2 |
7942847 | Stupecky et al. | May 2011 | B2 |
7998165 | Huffmaster | Aug 2011 | B2 |
8066667 | Hayman et al. | Nov 2011 | B2 |
8092508 | Leynov et al. | Jan 2012 | B2 |
8202292 | Kellett | Jun 2012 | B2 |
8206373 | Zhou | Jun 2012 | B2 |
8348890 | Gerrans et al. | Jan 2013 | B2 |
8961550 | Lenker et al. | Feb 2015 | B2 |
9005163 | Bonnette et al. | Apr 2015 | B2 |
9174020 | Allen et al. | Nov 2015 | B2 |
9205226 | Allen et al. | Dec 2015 | B2 |
9427550 | Dakin et al. | Aug 2016 | B2 |
9550046 | Allen | Jan 2017 | B1 |
9555165 | Phan | Jan 2017 | B2 |
9844383 | Allen | Dec 2017 | B2 |
10086174 | Crall et al. | Oct 2018 | B2 |
20010041862 | Glickman | Nov 2001 | A1 |
20020004666 | Schwager et al. | Jan 2002 | A1 |
20020032457 | Sirhan et al. | Mar 2002 | A1 |
20020193820 | Wakuda et al. | Dec 2002 | A1 |
20030050600 | Ressemann et al. | Mar 2003 | A1 |
20030114878 | Diederich et al. | Jun 2003 | A1 |
20030144657 | Bowe | Jul 2003 | A1 |
20030180488 | Lim et al. | Sep 2003 | A1 |
20030191435 | Shkolnik | Oct 2003 | A1 |
20030199914 | Diaz | Oct 2003 | A1 |
20030220628 | Kilsch et al. | Nov 2003 | A1 |
20040015151 | Chambers | Jan 2004 | A1 |
20040073158 | Shah | Apr 2004 | A1 |
20040167415 | Gelfand et al. | Aug 2004 | A1 |
20050131453 | Parodi | Jun 2005 | A1 |
20050267407 | Goldman | Dec 2005 | A1 |
20060106413 | Bence et al. | May 2006 | A1 |
20060149186 | Wantink et al. | Jul 2006 | A1 |
20060276886 | George et al. | Dec 2006 | A1 |
20070088380 | Hirszowicz et al. | Apr 2007 | A1 |
20070137651 | Glassenberg et al. | Jun 2007 | A1 |
20070149927 | Itou et al. | Jun 2007 | A1 |
20080033372 | Briscoe et al. | Feb 2008 | A1 |
20080045908 | Gould et al. | Feb 2008 | A1 |
20080208118 | Goldman | Aug 2008 | A1 |
20080262470 | Lee et al. | Oct 2008 | A1 |
20090131831 | Wright et al. | May 2009 | A1 |
20090156999 | Adams et al. | Jun 2009 | A1 |
20090177183 | Pinkernell et al. | Jul 2009 | A1 |
20100030200 | Strauss et al. | Feb 2010 | A1 |
20100113939 | Mashimo et al. | May 2010 | A1 |
20100222637 | Kassab | Sep 2010 | A1 |
20100249491 | Farnan et al. | Sep 2010 | A1 |
20120203173 | Davies et al. | Aug 2012 | A1 |
20120253447 | Hayasaka et al. | Oct 2012 | A1 |
20130131610 | Dewaele et al. | May 2013 | A1 |
20140163421 | Van Hoven | Jun 2014 | A1 |
20140371709 | Allen et al. | Dec 2014 | A1 |
20140371718 | Alvarez et al. | Dec 2014 | A1 |
20150112255 | Jensen et al. | Apr 2015 | A1 |
20150351729 | Chin et al. | Dec 2015 | A1 |
20160008585 | Tano | Jan 2016 | A1 |
20160096002 | Di Caprio et al. | Apr 2016 | A1 |
20160101261 | Kugler et al. | Apr 2016 | A1 |
20160158439 | Allen | Jun 2016 | A1 |
20160199067 | Smith et al. | Jul 2016 | A1 |
20160213893 | Franklin | Jul 2016 | A1 |
20170049495 | Yu et al. | Feb 2017 | A1 |
20170095646 | Norman et al. | Apr 2017 | A1 |
20170252542 | Iwano et al. | Sep 2017 | A1 |
20170303890 | Yamashita | Oct 2017 | A1 |
20180015248 | Logan et al. | Jan 2018 | A1 |
20180056036 | Wada et al. | Mar 2018 | A1 |
20180125502 | Allen | May 2018 | A1 |
20190329007 | Allen et al. | Oct 2019 | A1 |
20230226328 | Roewer et al. | Jul 2023 | A1 |
Number | Date | Country |
---|---|---|
101400400 | Apr 2009 | CN |
102159277 | Aug 2011 | CN |
102802698 | Nov 2012 | CN |
102805893 | Dec 2012 | CN |
103987421 | Aug 2014 | CN |
105246537 | Jan 2016 | CN |
105854151 | Aug 2016 | CN |
106422033 | Feb 2017 | CN |
102009025347 | Dec 2010 | DE |
202011003097 | Jul 2011 | DE |
0520692 | Dec 1992 | EP |
1131126 | Aug 2004 | EP |
2389968 | Nov 2011 | EP |
3132823 | Feb 2017 | EP |
2512696 | Oct 2014 | GB |
H03-207376 | Sep 1991 | JP |
H05-15604 | Jan 1993 | JP |
H06-277296 | Oct 1994 | JP |
H07-213617 | Aug 1995 | JP |
H10244006 | Sep 1998 | JP |
2003500121 | Jan 2003 | JP |
2005511108 | Apr 2005 | JP |
2006511271 | Apr 2006 | JP |
2007319468 | Dec 2007 | JP |
2008522716 | Jul 2008 | JP |
2008544801 | Dec 2008 | JP |
2011087971 | May 2011 | JP |
2011152181 | Aug 2011 | JP |
201290779 | May 2012 | JP |
2015523884 | Aug 2015 | JP |
2016517778 | Jun 2016 | JP |
20100006710 | Jul 2010 | KR |
WO8908471 | Sep 1989 | WO |
WO9948548 | Sep 1999 | WO |
WO2004107965 | Dec 2004 | WO |
WO2007121005 | Oct 2007 | WO |
WO2012009486 | Jan 2012 | WO |
WO2012099979 | Jul 2012 | WO |
WO2014008489 | Jan 2014 | WO |
WO2019236951 | Dec 2019 | WO |
WO2020023889 | Jan 2020 | WO |
Entry |
---|
Angiodynamics; Soft-vu angiographic catheters; 2 pages; retrieved from the internet (http://www.angiodynamics.com/products/soft-vu) on Aug. 17, 2018. |
BMI ESPICOM Pharmaceutical and Medical Device News; Business Monitor Online: Vascular solutions expands complex intervention offerings with turnpike LP catheter; newsleter; 2pages; retrieved from the internet (https://dialog.proquest.com/professional/docview/1753127273?accountid=157282) on Apr. 18, 2018 (Abstract Only). |
Cliffton et al.; Technique for visualization and perfusion of bronchial arteries: suggested clinical and diagnostic applications; Cancer; 16; pp. 444-452; Apr. 1963. |
Matsuda et al.; Electrospinning fabrication of high-trackable catheter tip with gradually graded or gradient flexibility; J. Biomed. Mater. Res. B Appl. Biomater.; 1(35); pp. 35-41 doi: 10.1002/jbm.b.31061; (Abstract Only); Oct. 2008. |
Nordson Medical; Extruded tubing technical information; 7 pages; retrieved from the internet (https://www.nordsonmedical.com/Components-and-Technologies/Medical-Tubing/Extruded-Tubing/Technical-Information/) on Aug. 17, 2018. |
Rousselot et al.; Selective concentration of anticancer drugs in the liver: Hepatic-artery infusion and induced hepatic outflow block; JAMA; 191(9); pp. 707-710; Mar. 1965. |
Vante Plasticweld Systems; Bonds and welds; 13 pages; retrieved from the internet (https://cathetertipping.com/home/our-products/bonding/) on Aug. 17, 2018. |
Worldwide Videotex; Angiodynamics PCTA balloon catheter gets FDA market clearance; Biotech Equipment Update 5.9: N/A. Worldwide Videotex; Sep. 1, 1997; 2 pages; retrieved from the internet (https://dialog.proquest.com/professional/docview/680080033?accountid=157282) on Apr. 18, 2018 (Abstract Only). |
Zeus; FluoroPEELZ peelable heat shrink; 9 pages; retrieved from the internet (https://www.zeusinc.com/products/heat-shrinkable-tubing/fluoropeelz-peelable-heat-shrink) on Aug. 17, 2018. |
Allen et al.; U.S. Appl. No. 15/413,262 entitled “Balloon catheter and methods of fabrication and use,” filed Jan. 23, 2017. |
Halstead et al.; U.S. Appl. No. 16/004,247 entitled “High torque catheter and methods of manufacture,” filed Jun. 8, 2018. |
Allen; U.S. Appl. No. 16/889,379 entitled “Devices and methods for low pressure tumor embolization,” filed Jun. 1, 2020. |
Allen U.S. Appl. No. 16/196,398 entitled “Device and methods for transvascular tumor embolization,” filed Nov. 20, 2018. |
Cook Medical; Flexor technology; 16 pages; retrieved from the internet (https:cookmedical.com/data/resources/PI-BM-KCF-EN-201302_WEB.pdf) on May 5, 2019. |
Halstead et al.; U.S. Appl. No. 16/545,519 entitled “Balloon catheters and methods of manufacture and use,” filed Aug. 20, 2019. |
Halstead et al.; U.S. Appl. No. 17/636,562 entitled “Catheters and methods of manufacture and use,” filed Feb. 18, 2022. |
Halstead et al.; U.S. Appl. No. 17/938,559 entitled “Balloon catheters and methods of manufacture and use,” filed Oct. 6, 2022. |
Number | Date | Country | |
---|---|---|---|
20200030577 A1 | Jan 2020 | US |